The clinical value of the Enzymun-Test® for total and free PSA - A multicentre evaluation

Anticancer Research

Volumn 19, Issue 6 C, 1999, Pages 5559-5562

  Reiter, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EVALUATION STUDIES; HUMANS; MALE; MULTICENTER STUDIES; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 0033367150     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy, GP, Chu TM: Prostate antigen: a new potential marker for prostatic cancer. Prostate 2: 89-96, 1981.
2. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
3. Fateh-Moghadam A, Stieber P: Sensible use of tumour markers. 2nd edition Jürgen Hartmann Verlag GmbH, Marloffstein-Rathsberg, Germany, 1993.
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tukkanen K, Alfthan O: A complex between prostate-specific antigen and alpha1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
5. Lilja H, Christensson A, Dahlen U, Matikainen M.-T, Nilsson O, Pettersson K, Lövgren, T: Prostate-specific antigen in serum occurs predominantly in compex with alpha1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
6. Catolona WJ, Smith DS: Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer 74: 1516-1518, 1994.
7. Partin AW, Kelly CA, Subong ENP, Walsh PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, Mc Cormack R: Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4 and 10 ng/ml. J Urol 153: 295A, 1995.
8. Prestigiacomo AF, Stamey TA: Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 55 (Suppl. 221): 323-324, 1995.
9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (18): 1214-1220, 1995.
10. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41(8): 1115-1120, 1995.
11. Blijenberg G, Eman I, Boeve E.R. Mössner E, Uhl W: The analytical and clinical performance of the new Boehringer Mannheim Enzymun-TestR PSA assay for prostate-specific antigen. Eur J Clin Chem Clin Biochem 33: 383-392, 1995.
12. Blijenherg G, Kessler A.-C, Uhl W: Multicentre evaluation of a new fully automated enzymun immunoassay for total prostate-specific antigen. Eur J Clin Chem Clin Biochem 33: 965-973, 1995.
13. Van Dalen A: Quality control and standardization of tumour marker tests. Tumor Biol 14: 131-135, 1993.
14. Kojima M, Babaian RJ: Algorithmus for early detection of prostate cancer. Current state of the "art". Cancer 75 (Suppl 7): 1860-1868, 1995.
15. Oesterling JE: Prostate specific antigen: its role in the diagnosis and staging of prostate cancer. Cancer 75 (Suppl 7): 1795-1804, 1995.
16. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan PC, de Kernion JB, Ratliff TL, Kavousi LR, Dalkin BL, Walters WB, Mac Farlane MT, Southwich PC: Comparison of digital examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6.630 men. J Urol 151: 1283-1290, 1994.
17. Wu JT Wilson L, Zhang P, Meikle AW, Stephenson R: Correlation of serum concentration of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 9: 15-24, 1995.
18. Wu JT: Assay for prostate specific antigen (PSA) problems and possible solutions. J Clin Lab Anal 8: 51-62, 1994.
19. Vessella RL: Trends in immunoassays of prostate- specific antigen: serum complexes and ultrasensitivity. Clin Chem 39: 2035-2039, 1993
20. Wang TJ, Hill T, Norton K, Sokoloff R, Frankenne F, Rittenhouse HG, Wolfert RL: Specific immunoassays for free PSA and its clinical relevance. J Urol 153 (Suppl.): 295A, 1995.
21. Wilson L, Stephenson R, Meikle W, Wu J: Measurement of serum PSA-ACT complex in patients with BPH and prostate cancer: feasibility and advantages. Clin Chem 40: 1004-1010, 1994.
22. Densel M, Rittenhouse H, Cazares L, Wolfert R: Detection of prostate specific antigen complexed to alpha J-antichymotrypsin (PSA/ACT) and uncomplexed PSA in serum from patients with benign prostate hypertrophy (BPH) and prostate cancer (PCA) using dual monoclonal assays. J Urol 149: 333A, 1993.
23. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG: Multiple forms of prostate-specific antigen in serum measured differently in equimolar- and skewed-response assays. Clin Chem 41: 125-126, 1995.
24. Schamheck, C.M, Schmeller, N, Stieber, P, Jansen, H,M, Pahl, H, Schneider, W, Fateh-Moghadam, A: Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen in prostate cancer. Urology 46: 195-199, 1995.